Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $5.9200 (13.19%) ($5.9200 - $5.9200) on Mon. Sep. 18, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.14% (three month average) | RSI | 49 | Latest Price | $5.9200(13.19%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA declines -0.4% a day on average for past five trading days. | Weekly Trend | IOVA declines -5.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IPO(93%) SLV(93%) LQD(86%) TIP(49%) PCY(40%) | Factors Impacting IOVA price | IOVA will decline at least -2.57% in a week (0% probabilities). UUP(-84%) USO(-57%) ICLN(-38%) UNG(-32%) ACES(-27%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.57% (StdDev 5.14%) | Hourly BBV | 1 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-6.88(-216.22%) | 5 Day Moving Average | $5.44(8.82%) | 10 Day Moving Average | $5.69(4.04%) | 20 Day Moving Average | $5.92(0%) | To recent high | -32.1% | To recent low | 27.4% | Market Cap | $867m | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |